Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Sep-Oct;50(5):284-286.
doi: 10.4103/ijp.IJP_547_17.

Rare occurrence of hand-foot syndrome due to paclitaxel: A rare case report

Pritam S Kataria  1 , Pradip P Kendre  1 , Apurva A Patel  2 , Nahush Tahiliani  1 , Vijay Bhargav  1 , Honey Parekh  1
Affiliations
Case Reports

Rare occurrence of hand-foot syndrome due to paclitaxel: A rare case report

Pritam S Kataria et al. Indian J Pharmacol. 2018 Sep-Oct.

Abstract

Hand-foot syndrome (HFS) is a relatively frequent adverse reaction to certain anticancer drugs. HFS is a type of dermatitis which has been most commonly described with 5-fluorouracil and capecitabine. However, HFS with paclitaxel is rare and has been reported sparingly in the literature. A 52-year-old male patient with recurrent carcinoma of the buccal mucosa was started on palliative chemotherapy regimen, injection paclitaxel (175 mg/m2) in combination with injection carboplatin. On post-chemotherapy day 13, the patient started developing pain, dysesthesia followed by bullae formation, and desquamation over palms and soles. Clinically, the patient had Grade 3 HFS characterized by symmetrical, tender skin lesions over the dorsal aspect of palms, and soles with desquamation necessitating interruption of treatment. Therefore, this case has been presented to be cognizant with this rare form of side effect with one of the most commonly used drug in oncology.

Keywords: Hand-foot syndrome; paclitaxel; pyridoxine.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Bilateral feet showing erythema with desquamation
Figure 2
Figure 2
Bilateral dorsum of hand showing erythema with desquamation
Figure 3
Figure 3
Bilateral feet showing erythema with desquamation
See this image and copyright information in PMC

References

    1. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda) Eur J Oncol Nurs. 2004;8(Suppl 1):S31–40. - PubMed
    1. Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 2004;18:1161–8, 1173. - PubMed
    1. Surjushe A, Vasani R, Medhekar S, Thakre M, Saple DG. Hand-foot syndrome due to capecitabine. Indian J Dermatol. 2009;54:301–2. - PMC - PubMed
    1. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology. 2009;77:257–71. - PubMed
    1. Akash S, Bhounsule AS. Oral capecitabine – Can it cause the hand-foot syndrome? J Clin Diagn Res. 2011;5:376–786.

Publication types

MeSH terms

Substances